Search details
1.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34310904
2.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33017510
3.
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
J Urol
; 203(1): 115-119, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31502940
4.
Exploration of baseline patient-reported side effect bother from cancer therapy.
Clin Trials
; 17(3): 332-337, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32153216
5.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist
; 24(4): 563-569, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30541754
6.
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Liver Int
; 38(6): 976-987, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29603856
7.
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Oncologist
; 22(6): 743-749, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28424325
8.
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Oncologist
; 21(5): 634-42, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26984449
9.
Bone-targeting agents in prostate cancer.
Cancer Metastasis Rev
; 33(2-3): 619-28, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24398856
10.
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Prostate
; 75(15): 1814-20, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-26306637
11.
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Prostate
; 74(13): 1278-85, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25053178
12.
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.
J Natl Cancer Inst
; 2024 Mar 14.
Article
in English
| MEDLINE | ID: mdl-38486364
13.
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res
; 30(10): 2011-2016, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38441576
14.
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
J Clin Oncol
; 42(14): 1687-1698, 2024 May 10.
Article
in English
| MEDLINE | ID: mdl-38484203
15.
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 2024 Feb 28.
Article
in English
| MEDLINE | ID: mdl-38416426
16.
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 42(5): 605-613, 2024 Feb 10.
Article
in English
| MEDLINE | ID: mdl-38127780
17.
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 42(15): 1851-1860, 2024 May 20.
Article
in English
| MEDLINE | ID: mdl-38452327
18.
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Eur Urol
; 84(4): 373-378, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37271635
19.
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 29(9): 1651-1657, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36469000
20.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Article
in English
| MEDLINE | ID: mdl-38084090